[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma

Inclusion Criteria:

1. Histologically proven diagnosis of B-cell non-Hodgkin's lymphoma, exclusivelylocalized in the central nervous system, cranial nerves, and/or eyes

2. No previous treatment; A tumorectomy on diagnostic purpose and/or use ofglucocorticoids is allowed

3. Measurable lesion(s)

4. Age ≥ 60 years

5. Unfit patients for high-dose chemotherapy followed by autologous stem celltransplantation

6. Adequate organ functions

• Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L

• Platelets ≥ 50 x 109/L

• Hemoglobin ≥ 8.0 g/dL

• Serum Creatinine ≤ 1.5 x upper limit normal (ULN)

• Serum Bilirubin ≤ 1.5 x ULN

• AST and ALT ≤ 3 x ULN

7. Patients with adequately controlled HBV, HCV or HIV are allowed. In case of HBV (+),adequate anti-viral prophylaxis should be incorporated. In case of HIV (+), highlyactive anti-retroviral therapy should be incorporated.

8. Written informed consent

9. ECOG performance scale 0, 1 or 2

10. Life expectancy > 3 months

Exclusion Criteria:

1. T-cell or NK/T cell lymphoma

2. Any evidence of systemic non-Hodgkin's lymphoma as demonstrated by computed tomographyscan of the neck, chest, abdomen, and pelvis and bone marrow examinations

3. Young and fit patients who are suitable for high-dose chemotherapy followed byautologous stem cell transplantation

4. Prior radiation therapy on target CNS lesion(s)

5. Concurrent severe or uncontrolled medical conditions, laboratory abnormalities orpsychiatric disorders that would preclude the participants in the study by thediscretion of attending physicians

6. Metachronous malignancy other than adequately treated basal cell or squamous cellcarcinoma of the skin, or CIN of uterine cervix, or prostate cancer that can beobserved without treatment

7. Known hypersensitivity to the investigational agent(s)